|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Synthorx_(2019)
gptkb:Genzyme_(2011)
Bioverativ (2018)
Principia Biopharma (2020)
Kymab (2021)
|
|
gptkbp:CEO
|
gptkb:Paul_Hudson
|
|
gptkbp:chairman
|
gptkb:Serge_Weinberg
|
|
gptkbp:country
|
gptkb:France
|
|
gptkbp:focusArea
|
gptkb:diabetes
immunology
oncology
vaccines
rare diseases
|
|
gptkbp:formerName
|
gptkb:Sanofi-Synthélabo
gptkb:Aventis
|
|
gptkbp:founded
|
2004
|
|
gptkbp:founder
|
merger of Sanofi-Synthélabo and Aventis
|
|
gptkbp:headquarters_location
|
gptkb:Paris
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sanofi Aventis
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
FR0000120578
|
|
gptkbp:keyPerson
|
gptkb:Paul_Hudson
gptkb:Serge_Weinberg
|
|
gptkbp:listedOn
|
gptkb:NYSE
gptkb:CAC_40
|
|
gptkbp:member
|
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
€6.7 billion (2022)
|
|
gptkbp:notable_drug
|
gptkb:Myozyme
gptkb:Aubagio
gptkb:Clexane
gptkb:Dupixent
gptkb:Kevzara
gptkb:Lantus
gptkb:Plavix
gptkb:Praluent
gptkb:Toujeo
|
|
gptkbp:notable_vaccine
|
gptkb:Adacel
gptkb:Vaxigrip
gptkb:Fluzone
gptkb:Menactra
gptkb:Pentacel
|
|
gptkbp:numberOfEmployees
|
over 100,000
|
|
gptkbp:parentOrganization
|
gptkb:Sanofi
|
|
gptkbp:products
|
vaccines
pharmaceutical drugs
|
|
gptkbp:revenue
|
€36.1 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Euronext_Paris
|
|
gptkbp:stockSymbol
|
gptkb:SNY
SAN
|
|
gptkbp:subsidiary
|
gptkb:Sanofi_Pasteur
gptkb:Genzyme
|
|
gptkbp:website
|
https://www.sanofi.com/
|
|
gptkbp:bfsParent
|
gptkb:Sanofi
|
|
gptkbp:bfsLayer
|
5
|